Skip to Content
MilliporeSigma
All Photos(1)

Documents

SML2633

Sigma-Aldrich

Sorafenib tosylate

≥98% (HPLC)

Synonym(s):

4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide, 4-methylbenzenesulfonate, BAY 43-9006 tosylate salt, BAY43-9006 tosylate salt, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N′-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea, 4-methylbenzenesulfonate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C21H16ClF3N4O3·C7H8SO3
CAS Number:
475207-59-1
Molecular Weight:
637.03
MDL number:
MFCD08235032
UNSPSC Code:
12352200
NACRES:
NA.77

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to very dark brown

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

InChI

1S/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31);2-5H,1H3,(H,8,9,10)

InChI key

IVDHYUQIDRJSTI-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Tosylate salt of the orally active kinase inhibitor Sorafenib (BAY 43-9006) that exerts broad-spectrum anticancer efficacy in vitro and in vivo via targeting b-Raf, c-Raf (Raf-1), as well as several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular endothelial growth factor receptors 2/3 (VEGFR-2/Flk-1/KDR, VEGFR-3), platelet-derived growth factor receptor-beta (PDGFR-β), Flt-3, c-KIT, FGFR-1 (Flt-2) and RET.

pictograms

Health hazardEnvironment
GHS08,GHS09

signalword

Danger

Hazard Classifications

Aquatic Acute 1 - Aquatic Chronic 1 - Lact. - Repr. 1B - STOT RE 1

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Şükran Alpdemir et al.
IET nanobiotechnology, 14(7), 617-622 (2020-10-04)
This study aimed to develop sorafenib loaded magnetic microspheres for the treatment of hepatocellular carcinoma. To achieve this goal, superparamagnetic iron oxide nanoparticles (SPIONs) were synthesised and encapsulated in alginate microspheres together with an antineoplastic agent, sorafenib. In the study
Pan Liang et al.
International journal of pharmaceutics, 583, 119375-119375 (2020-04-29)
A novel nanocrystals delivery system of parthenolide (PTL) was designed to combined application with sorafenib (Sora) for advanced hepatocellular carcinoma (HCC) therapy, attempting to not only improve the poor aqueous solubility of PTL, but also enhance the synergistic therapeutic effects
Agnieszka Karbownik et al.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 130, 110530-110530 (2020-07-28)
Sorafenib (SR) is one of the most potent UGT (1A1, 1A9) inhibitors (in in vitro tests). The inhibition of UGT1A1 may cause hyperbilirubinaemia, whereas the inhibition of UGT1A9 and 1A1 may result in drug-drug interactions (DDIs). Tapentadol (TAP) is a
Agnieszka Karbownik et al.
European journal of drug metabolism and pharmacokinetics, 45(6), 801-808 (2020-08-11)
Sorafenib is an oral, multikinase inhibitor with established single-agent activity in several tumor types. Sorafenib was moderately transported by P-glycoprotein (P-gp) and more efficiently by breast cancer resistance protein. The constitutive androstane receptor (CAR) is a ligand-activated transcription factor involved
Tomomi Hashiba et al.
Cellular and molecular gastroenterology and hepatology, 10(2), 269-285 (2020-03-15)
Sorafenib is a multireceptor tyrosine kinase inhibitor that can prolong overall survival in patients with advanced hepatocellular carcinoma (HCC). Although most HCC patients who receive sorafenib ultimately show disease progression, it still is unclear whether and how HCC cells acquire
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service